[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

1 followed by vaccinia with two shots of vaccinia.
2 And the conclusion of two studies because
3 the first did not agree with the anticipated results
4 -- but both of these studies concluded that gp 160 was
5 just as good as the vaccinia finding followed by gp
6 160.
7 I have several additional, and you can
8 answer these when I complete these other questions
9 here. The others are technical points, not points
10 raised by discordant observations and results, at
11 least by the NIAID program, of which you are a part.
12 One is I'd like to know what challenge
13 viruses you used in your comparative studies. My
14 understanding is that some strains, like SF and MN,
15 that were used to produce your five mutualizing
16 antibody titers, are actually much more ECP
17 neutralized in R&D.
18 Secondly, I understand there's an
19 algorithm that --
20 CO-CHAIRMAN FAUCI: Can we do this --
21 MR. VOLVOVITZ: Let me finish.
22 CO-CHAIRMAN FAUCI: Oh, okay.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
(202) 234- 4433 WASH INGTON, D.C. 20005 ( 202) 234- 4433